Search results
Showing 61 to 75 of 162 results for atrial fibrillation
ID NG196/2 Question Tests to diagnose paroxysmal atrial fibrillation: What is the diagnostic accuracy of key index tests compared with
percentage of patients with one or more of the following conditions: CHD, atrial fibrillation, chronic heart failure, stroke or TIA,...
Carnation Ambulatory Monitor for ambulatory detection of cardiac arrythmias (MIB276)
NICE has developed a medtech innovation briefing (MIB) on Carnation Ambulatory Monitor for ambulatory detection of cardiac arrythmias .
ID NG196/1 Question Tests to diagnose persistent atrial fibrillation: What is the diagnostic accuracy of key index tests (such as the...
and cost effectiveness of stopping anticoagulation in people whose atrial fibrillation has resolved after ablation? Any explanatory...
Rate-control drug treatment for people aged 75 and over with atrial fibrillation: What is the comparative effectiveness of the 3 main...
balloon cryoablation in relation to other procedures for treating atrial fibrillation. Further research should define patient selection...
from UK primary care databases clarify stroke risk in people with atrial fibrillation according to baseline risk factors and treatment?...
Find out more about the progress made in implementing NICE guidance on cardiovascular disease prevention
Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49)
This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.
Irreversible electroporation for treating liver metastases (IPG445)
Evidence-based recommendations on irreversible electroporation for the treatment of liver metastases. This involves using very short electrical field pulses delivered over several minutes to destroy the tumour and a small surrounding tissue margin.
View recommendations for IPG445Show all sections
Sections for IPG445
Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)
Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making
Supporting the health and care system in improving productivity
Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.
VERO and NObreath April 2014 DG12 Review decision DG14 Atrial fibrillation and heart valve disease: self-monitoring coagulation status...